1Verma, Focus on Potential Role of Recombinant AntiPCSK9Monoclonal Antibodies.Rev Cardiovasc Med,2014,15 (2) :86-101. 被引量:1
2Zhao S.Prevalence of dyslipidaemia in patients treated withlipidlowering agents in China Results of DYSIS. Atherosclerosis, 2014,235(2):463-469. 被引量:1
3Stock.Improving the care of high-risk patients:potential of PCSK9.Atherosclerosis,2014,232 (2) :420-422. 被引量:1